Literature DB >> 2371289

Vaccination with a live retrovirus: the nature of the protective immune response.

R M Ruprecht1, S Mullaney, L D Bernard, M A Gama Sosa, R C Hom, R W Finberg.   

Abstract

We tested 3'-azido-3'-deoxythymidine (zidovudine) combined with interferon alpha as chemoprophylaxis after exposing mice to Rauscher murine leukemia virus. Therapy started 4 hr after inoculation and administered for 20 days prevented viremia and disease in all 234 mice tested. When the animals were rechallenged with live virus after cessation of therapy, 96% were resistant. The nature of this protective immune response was analyzed: Passive serotherapy of naive mice challenged subsequently with Rauscher murine leukemia virus was only protective at a high dose of immune serum. Immune, but not naive, T cells alone were fully protective against virus challenge. We conclude that vaccination with a live retrovirus that cannot replicate because of pharmacological blockade induces a T-cell response capable of protecting against a lethal retrovirus-induced disease.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2371289      PMCID： PMC54364          DOI： 10.1073/pnas.87.14.5558

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  27 in total

1.  STUDIES WITH THE MURINE LEUKEMOGENIC RAUSCHER VIRUS. 3. AN IN VIVO ASSAY FOR ANTI-VIRAL AGENTS.

Authors:  M A CHIRIGOS
Journal:  Cancer Res       Date:  1964-07       Impact factor: 12.701

2.  Synthesis of avian oncornavirus DNA in infected chicken cells.

Authors:  M Ali; M A Baluda
Journal:  J Virol       Date:  1974-05       Impact factor: 5.103

3.  Passive immunotherapy prevents expression of endogenous Moloney virus and amplification of proviral DNA in BALB/Mo mice.

Authors:  P Nobis; R Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205

4.  Immunoprevention of Friend virus-induced erythroleukemia by vaccination with viral envelope glycoprotein complexes.

Authors:  G Hunsmann; J Schneider; A Schulz
Journal:  Virology       Date:  1981-09       Impact factor: 3.616

5.  Plaque assay techniques for murine leukemia viruses.

Authors:  W P Rowe; W E Pugh; J W Hartley
Journal:  Virology       Date:  1970-12       Impact factor: 3.616

6.  Suppression of retroviral propagation and disease by suramin in murine systems.

Authors:  R M Ruprecht; L D Rossoni; W A Haseltine; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

7.  Cell-mediated immunity against herpes simplex induction of cytotoxic T lymphocytes.

Authors:  M J Lawman; B T Rouse; R J Courtney; R D Walker
Journal:  Infect Immun       Date:  1980-01       Impact factor: 3.441

8.  Suppression of mouse viraemia and retroviral disease by 3'-azido-3'-deoxythymidine.

Authors:  R M Ruprecht; L G O'Brien; L D Rossoni; S Nusinoff-Lehrman
Journal:  Nature       Date:  1986 Oct 2-8       Impact factor: 49.962

9.  Mouse immunoglobulin antibodies require complement for neutralization of mouse retroviruses.

Authors:  P S Sarma; W P Rowe
Journal:  J Virol       Date:  1983-03       Impact factor: 5.103

10.  Role of viral infectivity in the induction of influenza virus-specific cytotoxic T cells.

Authors:  T J Braciale; K L Yap
Journal:  J Exp Med       Date:  1978-04-01       Impact factor: 14.307
View more
  9 in total

1.  Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment.

Authors:  J D Lifson; J L Rossio; R Arnaout; L Li; T L Parks; D K Schneider; R F Kiser; V J Coalter; G Walsh; R J Imming; B Fisher; B M Flynn; N Bischofberger; M Piatak; V M Hirsch; M A Nowak; D Wodarz
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Effect of zidovudine on the primary cytolytic T-lymphocyte response and T-cell effector function.

Authors:  S Francke; C G Orosz; K A Hayes; L E Mathes
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

3.  Evidence that high-dosage zidovudine at time of retrovirus exposure reduces antiviral efficacy.

Authors:  L E Mathes; K A Hayes; G Kociba
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

4.  Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques.

Authors:  Jörn E Schmitz; R Paul Johnson; Harold M McClure; Kelledy H Manson; Michael S Wyand; Marcelo J Kuroda; Michelle A Lifton; Rajinder S Khunkhun; Kimberly J McEvers; Jacqueline Gillis; Michael Piatak; Jeffrey D Lifson; Gudrun Grosschupff; Paul Racz; Klara Tenner-Racz; E Peter Rieber; Kristine Kuus-Reichel; Rebecca S Gelman; Norman L Letvin; David C Montefiori; Ruth M Ruprecht; Ronald C Desrosiers; Keith A Reimann
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 5.  The gag proteins of human immunodeficiency virus type 1: mechanisms of virus assembly and possibilities for interference.

Authors:  S Modrow; B Kattenbeck; A von Poblotzki; M Niedrig; R Wagner; H Wolf
Journal:  Med Microbiol Immunol       Date:  1994-09       Impact factor: 3.402

6.  Vaccination by delayed treatment of infection.

Authors:  Sean P Stromberg; Rustom Antia
Journal:  Vaccine       Date:  2011-10-30       Impact factor: 3.641

7.  Pre- and postexposure chemoprophylaxis: evidence that 3'-azido-3'-dideoxythymidine inhibits feline leukemia virus disease by a drug-induced vaccine response.

Authors:  L E Mathes; P J Polas; K A Hayes; C L Swenson; S Johnson; G J Kociba
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

8.  Protective cellular retroviral immunity requires both CD4+ and CD8+ immune T cells.

Authors:  R C Hom; R W Finberg; S Mullaney; R M Ruprecht
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

9.  Integrating Antimicrobial Therapy with Host Immunity to Fight Drug-Resistant Infections: Classical vs. Adaptive Treatment.

Authors:  Erida Gjini; Patricia H Brito
Journal:  PLoS Comput Biol       Date:  2016-04-14       Impact factor: 4.475
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.